7 completed, 5 terminated. 9 Phase 2, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Terminated 3 |
| Phase 1 | 7 | Completed 4, Terminated 3 |
Follow Squamous Cell Carcinoma of the Head and Neck (SCCHN): new trials by email Literature Review of Squamous Cell Carcinoma of the Head and Neck (SCCHN) trials Research Report on Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies PF-08046037, sasanlimab - Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal | Phase 1 | Terminated | Pfizer | 8 | 2025-05-06 | 2026-04-23 |
| Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC Duvelisib, Docetaxel - Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Completed | Kartik Sehgal, MD | 26 | 2021-10-14 | 2026-09-29 |
| Study of INCA 0186 in Subjects With Advanced Solid Tumors INCA00186, Retifanlimab, INCB106385 - Advanced Solid Tumors, Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Phase 1 | Terminated | Incyte Corporation | 57 | 2021-10-04 | 2025-09-02 |
| Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors avelumab, Bempegaldesleukin, talazoparib - Squamous Cell Carcinoma of the Head and Neck (SCCHN), Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 1 / Phase 2 | Terminated | Pfizer | 3 | 2019-12-30 | 2021-10-14 |
| Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer Panitumumab-IRDye800, Lymphoseek - Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Phase 2 | Completed | Eben Rosenthal | 3 | 2019-08-01 | 2022-11-10 |
| A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies INCAGN02385 - Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer | Phase 1 | Completed | Incyte Biosciences International Sàrl | 22 | 2018-06-18 | 2020-10-30 |
| Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer palbociclib, Cetuximab, Placebo - Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Phase 2 | Completed | Pfizer | 125 | 2015-09-10 | 2023-09-08 |
| A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors Combination of varlilumab and nivolumab - Squamous Cell Carcinoma of the Head and Neck (SCCHN), Ovarian Carcinoma-Enrollment Completed | Phase 1 / Phase 2 | Completed | Celldex Therapeutics | 175 | 2015-01-01 | 2019-12-09 |
| Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors Tisotumab Vedotin (HuMax-TF-ADC) - Ovary Cancer, Cervix Cancer | Phase 1 / Phase 2 | Completed | Seagen Inc. | 195 | 2013-11-30 | 2021-12-29 |
| Study of PX-866 and Docetaxel in Solid Tumors Docetaxel, PX-866 - Non Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Phase 1 / Phase 2 | Completed | Cascadian Therapeutics Inc. | 223 | 2010-09-01 | 2018-05-16 |
| A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck AT-101, Docetaxel - Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Phase 2 | Terminated | University of Michigan Rogel Cancer Center | 35 | 2010-06-01 | 2016-03-31 |
| Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck Bevacizumab, erlotinib, Sulindac - Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Phase 2 | Terminated | Massachusetts General Hospital | 36 | 2006-10-01 | 2017-04-13 |
Squamous Cell Carcinoma of Head and Neck (12) · Carcinoma, Non-Small-Cell Lung (3) · Head and Neck Neoplasms (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Renal Cell (2) · Colorectal Neoplasms (2) · Esophageal Neoplasms (2) · Melanoma (2) · Ovarian Neoplasms (2) · Uterine Cervical Neoplasms (2) · Carcinoma, Merkel Cell (1) · Carcinoma, Pancreatic Ductal (1) · Carcinoma, Squamous Cell (1) · Carcinoma, Transitional Cell (1) · Endometrial Neoplasms (1)
Carcinoma (12) · Neoplasms by Histologic Type (12) · Neoplasms by Site (12) · Neoplasms, Glandular and Epithelial (12) · Carcinoma, Squamous Cell (11) · Neoplasms (11) · Head and Neck Neoplasms (9) · Digestive System Diseases (5) · Digestive System Neoplasms (5) · Adenocarcinoma (4) · Gastrointestinal Diseases (4) · Gastrointestinal Neoplasms (4) · Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3) · Endocrine Gland Neoplasms (3)
Docetaxel (3) · Bevacizumab (1) · Cetuximab (1) · Erlotinib Hydrochloride (1) · Nivolumab (1) · PX-866 (1) · Sulindac (1) · avelumab (1) · bempegaldesleukin (1) · duvelisib (1) · enzalutamide (1) · gossypol acetic acid (1) · palbociclib (1) · talazoparib (1) · technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran (1)
Pfizer (3) · Cascadian Therapeutics Inc. (1) · Celldex Therapeutics (1) · Eben Rosenthal (1) · Incyte Biosciences International Sàrl (1) · Incyte Corporation (1) · Kartik Sehgal, MD (1) · Massachusetts General Hospital (1) · Seagen Inc. (1) · University of Michigan Rogel Cancer Center (1)
United States (12) · Belgium (3) · Spain (3) · Poland (2) · United Kingdom (2) · Austria (1) · Canada (1) · Czechia (1) · Denmark (1) · Hungary (1) · Italy (1) · Japan (1) · Mexico (1) · Netherlands (1) · Puerto Rico (1)
Francis Worden, MD (1) · Fred M Baik (1) · Ilona Rybicka, MD (1) · Jochen Lorch, MD (1) · Johann de Bono, Professor (1) · John Janik, MD (1) · Kartik Sehgal, MD (1)
PMID 30745090, PMID 31796521, PMID 33571736, PMID 35940825, PMID 37496366, PMID 41044356, PMID 42201333
2015 (1), 2019 (1), 2025 (1), P30CA124435 (1), R01CA190306 (1)